CD8A and neoplasm: As stated above, the molecular mechanism by which PMG5 promotes its adjuvant effect is not definitively understood; however, from our investigative in vivo data into the cellular mechanisms (Fig. 7), it was revealed that PMG5 could significantly enhance (compared to all other treatment groups) the accumulation of CD8+ T cells at the site of the tumor (both intratumorally and peritumorally at the site of PMG5 administration).